T1	Participants 407 429	in Australia and China
T2	Participants 760 827	33 protocol compliant Brisbane recipients of placebo immunotherapy,
T3	Participants 1033 1097	102 protocol compliant Brisbane recipients of VLP immunotherapy,
T4	Participants 1689 1728	168 Wenzhou protocol compliant subjects
T5	Participants 1937 1990	patients for whom destructive therapy is unsuccessful